FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.
The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said.